blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4054549

EP4054549 - TOPICAL FORMULATIONS OF CYCLOOXYGENASE INHIBITORS AND THEIR USE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  12.08.2022
Database last updated on 02.07.2024
FormerThe international publication has been made
Status updated on  14.05.2021
Most recent event   Tooltip17.05.2024Amendment by applicant 
Applicant(s)For all designated states
Smartech Topical, Inc.
10054 Prospect Ave Suite A
Santee, CA 92071 / US
[2022/37]
Inventor(s)01 / HNAT, Thomas
11241 Provencal Place
San Diego, California 92128 / US
 [2022/37]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2022/37]
Application number, filing date20885491.905.11.2020
[2022/37]
WO2020US59198
Priority number, dateUS201962931466P06.11.2019         Original published format: US 201962931466 P
[2022/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021092238
Date:14.05.2021
Language:EN
[2021/19]
Type: A1 Application with search report 
No.:EP4054549
Date:14.09.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 14.05.2021 takes the place of the publication of the European patent application.
[2022/37]
Search report(s)International search report - published on:US14.05.2021
(Supplementary) European search report - dispatched on:EP06.11.2023
ClassificationIPC:A61K31/196, A61K47/10, A61K47/14, A61K47/44, A61K9/06
[2023/49]
CPC:
A61K9/0014 (EP,US); A61K31/196 (EP,US); A61K31/165 (US);
A61K31/167 (US); A61K31/192 (US); A61K31/245 (US);
A61K31/405 (US); A61K31/416 (US); A61K31/60 (US);
A61K31/7034 (US); A61K47/10 (EP,US); A61K47/12 (EP,US);
A61K47/20 (EP,US); A61K47/38 (EP,US); A61K9/06 (EP) (-)
Former IPC [2022/37]A61K31/196, A61K47/10, A61K47/14, A61K47/44, A61K9/00, A61K9/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/37]
TitleGerman:TOPISCHE FORMULIERUNGEN VON CYCLOOXYGENASE-INHIBITOREN UND DEREN VERWENDUNG[2022/37]
English:TOPICAL FORMULATIONS OF CYCLOOXYGENASE INHIBITORS AND THEIR USE[2022/37]
French:FORMULATIONS TOPIQUES D'INHIBITEURS DE LA CYCLO-OXYGÉNASE ET LEUR UTILISATION[2022/37]
Entry into regional phase02.06.2022National basic fee paid 
02.06.2022Search fee paid 
02.06.2022Designation fee(s) paid 
02.06.2022Examination fee paid 
Examination procedure02.06.2022Examination requested  [2022/37]
16.05.2024Amendment by applicant (claims and/or description)
16.05.2024Date on which the examining division has become responsible
Fees paidRenewal fee
02.06.2022Renewal fee patent year 03
18.02.2024Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.11.202304   M06   Fee paid on   18.02.2024
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2011063531  (NUVO RES INC [CA], et al) [X] 1-15 * the whole document * * examples 1-14; claims 1-77; tables 1-22 *;
 [Y]EP2968214  (VAPOGENIX INC [US]) [Y] 1-15 * the whole document ** claims 1-15 *;
 [Y]WO2017173269  (SMARTECH TOPICAL LLC [US]) [Y] 1-15 * the whole document * * examples 1-6; claims 1-15 *
International search[XYA]WO2014143964  (VAPOGENIX INC [US]) [X] 1-3, 7/1-3, 8/1-3 * ; page 14, In 25-30; page 27, In 10; claims 1, 8-9, 12, 18, 20-21, 33, 35e * [Y] 4, 7/4, 8/7/4, 16-20 [A] 5-6, 7/5-6, 8/7/5-6;
 [YA]WO2017173269  (SMARTECH TOPICAL LLC [US]) [Y] 17 * ; paragraphs [0050]-[0051] * [A] 5-6, 7/5-6, 8/7/5-6;
 [YA]WO2018203040  (MEDHERANT LTD [GB]) [Y] 18 * ; paragraphs [0013]-[0014] * [A] 5-6, 7/5-6, 8/7/5-6;
 [YA]US2019046438  (HNAT THOMAS [US]) [Y] 4, 7/4, 8/7/4, 16-20. * ; paragraphs [0019], [0068], [0072], [0096], [0102]; claims 1, 3, 4 * [A] 5-6, 7/5-6, 8/7/5-6;
 [A]  - OSBORNE, DW, "Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products", Journal of Cosmetic Dermatology, (20111200), vol. 10, no. 4, doi:10.1111/j.1473-2165.2011.00590.x, pages 324 - 329, XP055014454 [A] 1-8, 16-20

DOI:   http://dx.doi.org/10.1111/j.1473-2165.2011.00590.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.